


Heterodimer-
Promoting Domain
VH(PD-1 or LAG-3)
COOH
Linker
Linker
Polypeptide Chains 2 and 4
Cysteine
Residues
NH2
VL(LAG-3 or PD-1)
NH2
VL(PD-1 or LAG-3)
Heterodimer-
Promoting Domain
Linker
Linker
VH(LAG-3 or PD-1)
COOH
Linker
CH3
CH2
Polypeptide Chains 1 and 3
Bi-Specific Tetra-Valent
Fc-Diabody
COOH
COOH
Fc Domain
COOH
NH2
NH2
COOH
NH2
COOH
COOH
Alternatives

Figure 1



+ 1 MG (N=1); ◆ 3 MG (N=1); □ 10 MG (N=4); ▲ 30 MG (N=5);
◊ 120 MG (N=6); ■ 400 MG (N=9); ○ 600 MG (N=8)
▼ 800 MG (N=7); ● 1200 MG (N=4)

Figure 2

CYCLE 1 DAY 1: CD4+ RECEPTOR OCCUPANCY BY DOSE




Figure 3A

CYCLE 1 DAY 1: CD8+ RECEPTOR OCCUPANCY BY DOSE




Figure 3B

CYCLE 2 DAY 1: CD4+ RECEPTOR OCCUPANCY BY DOSE




Figure 3C

CYCLE 2 DAY 1: CD8+ RECEPTOR OCCUPANCY BY DOSE




Figure 3D

PK SIMULATIONS FOR Q2W DOSING




Figure 4A

PK SIMULATIONS FOR Q3W DOSING




Figure 4B

PK SIMULATIONS FOR Q4W DOSING




Figure 4C



Cholang: Cholangiocarcinoma
NSCLC: Non-Small Cell Lung Cancer
SCLC: Small Cell Lung Cancer
EOC: Epithelial Ovarian Cancer
SCCHN: Squamous Cell Carcinoma of the Head and Neck
TNBC: Triple Negative Breast Cancer
a -- EOC
b -- SCCHN (POST CKPT)
c -- Cholang
d -- TNBC
e -- NSCLC (CKPT NAIVE)
f -- Cervical
g -- NSCLC (POST CKPT)
h -- SCLC
i -- SCCHN (CKPT NAIVE)
*=Ongoing
100
90
80
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80
-90

Figure 5



Figure 6A




Figure 6B




Figure 6C




Figure 6D




Figure 6E




Figure 7




Figure 8




Figure 9




Figure 10



NK
Monocyte
CD4 T
CD8 T
Control Ab
Marge
Lag-3
PD-1
PDL-1
CD137
0.39
18.8
34.1
98.0
0.59
5.72
1.62
23.1
0.099
0.17
0.33
0.14
3.92
6.77
6.93
8.62
0.48
27.0
11.9
99.9
0.038
1.87
0.69
9.41
1.97
28.0
0.22
0.047
0.50
0.32
0.69
0.54

Figure 11




Figure 12




Figure 13



Change from Baseline (%)
80
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80
EO - Epithelial ovarian cancer
CH - Cholangiocarcinoma
CR - Colorectal cancer
CV - Cervical cancer
GE - Gastroesophageal Junction carcinoma
BC - Breast cancer
ED - Endometrial cancer
EA - Esophageal adenocarcinoma
UC - Urethral carcinoma
DART-I 300 mg + margetuximab 15/mg/kg Q3W
DART-I 600 mg + margetuximab 15/mg/kg Q3W
+ Prior CPI therapy * Ongoing # Prior HER2-directed therapy
PD – progressive disease
SD – stable disease
cPR – confirmed partial response
uPR – unconfirmed partial response
cCR – confirmed complete response

Figure 14




Figure 15A




Figure 15B



100
80
60
40
20
0
PDCD1
-80
-60
-40
-20
0
20
40
60
% Change in Target Lesion
CR/PR
SD
PD
Correlation
Pearson
r=-0.3815
R2=0.1455

Figure 15C